• Product NameOCIAD1 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAffinity chromatography purified via peptide column
• ApplicationsELISA WB
• Species ReactivityHu
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a 16 amino acid peptide from near the carboxy terminus of human OCIAD1.
• Target NameOCIAD1
• Alternative Names    OCIAD1, Ovarian cancer immuno-reactive antigen domain-containing protein 1, OCIA domain-containing protein 1
• Accession No. Swiss-Prot:Q9NX40
  Gene ID:54940
• UniprotQ9NX40
• Gene ID54940;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

OCIAD1 was identified via immunoscreening of an ovarian carcinoma cDNA library from ovarian cancer patients and is expressed in multiple tissues including ovary, placenta, brain, testis, prostate, and mammary gland. Two isoforms of OCIAD1 are known to exist; the shorter isoform is restricted to the central nervous system. OCIAD1 is a transmembrane protein whose overexpression in HEY ovarian cancer cells increased lysophosphatidic acid- (LPA-)induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin10/11. This adhesion is not blocked by LY294002 and GF109203X, suggesting that OCIAD1 does not use protein kinase C and PI3 kinase signaling pathways to exert its effect on adhesion.

• Western blot analysis of OCIAD1 in 293 cell lysate with OCIAD1 antibody at (A) 1 and (B) 2 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting